{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:54:24Z","timestamp":1790178864775,"version":"4.1.0"},"reference-count":98,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Taiwan","award":["FEMH-YZU-2021-015"],"award-info":[{"award-number":["FEMH-YZU-2021-015"]}]},{"name":"Boehringer Ingelheim Taiwan","award":["FEMH-2022-C-020"],"award-info":[{"award-number":["FEMH-2022-C-020"]}]},{"name":"Far Eastern Memorial Hospital","award":["FEMH-YZU-2021-015"],"award-info":[{"award-number":["FEMH-YZU-2021-015"]}]},{"name":"Far Eastern Memorial Hospital","award":["FEMH-2022-C-020"],"award-info":[{"award-number":["FEMH-2022-C-020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by airway limitation and changes in airway structure. It has a high global burden of mortality and morbidity. The etiology of COPD is complex, but exposure to tobacco smoke and other inhaled lung oxidants are major risk factors. Both pharmacological and non-pharmacological approaches are used to manage COPD, but there remains an urgent unmet need for drugs that can modify the course of the disease. This review focuses on the role of acetylcholine and other components of the pulmonary cholinergic system in the pathogenesis of COPD, and the inhaled pharmacological agents that target it. In addition to its role as a neurotransmitter, acetylcholine regulates diverse aspects of COPD pathogenesis including bronchoconstriction, airway remodeling, mucus secretion and inflammation. Inhaled antimuscarinic drugs are a key component of therapy for COPD, as monotherapy or in combination with inhaled \u03b22 agonists or corticosteroids. We review the evidence supporting the use of current anticholinergic agents in COPD and preview novel drugs targeting the cholinergic system and agents from other classes in clinical development, such as phosphodiesterase-4 inhibitors and monoclonal antibodies targeting inflammatory mediators.<\/jats:p>","DOI":"10.3390\/biom13030476","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:49:08Z","timestamp":1678074548000},"page":"476","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System"],"prefix":"10.3390","volume":"13","author":[{"given":"Felisbela","family":"Gomes","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 22000, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-3157","authenticated-orcid":false,"given":"Shih-Lung","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 22000, Taiwan"},{"name":"Department of Chemical Engineering and Materials Science, Yuan-Ze University, Taoyuan 32056, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (2022, December 01). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2023 Report). Available online: https:\/\/goldcopd.org\/2023-gold-report-2\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15076","DOI":"10.1038\/nrdp.2015.76","article-title":"Chronic obstructive pulmonary disease","volume":"1","author":"Barnes","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e069679","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990\u20132019: Results from the Global Burden of Disease Study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"ref_4","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1164\/rccm.202005-1990OC","article-title":"Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study","volume":"203","author":"Burney","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1378\/chest.10-1253","article-title":"COPD in never smokers: Results from the population-based burden of obstructive lung disease study","volume":"139","author":"Lamprecht","year":"2011","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JXX.0000000000000627","article-title":"Understanding the genetics of chronic obstructive pulmonary disease, \u03b11-antitrypsin deficiency, and implications for clinical practice","volume":"33","author":"Mammen","year":"2021","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1700610","DOI":"10.1183\/13993003.00610-2017","article-title":"European Respiratory Society statement: Diagnosis and treatment of pulmonary disease in \u03b1(1)-antitrypsin deficiency","volume":"50","author":"Miravitlles","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/17476348.2022.2108797","article-title":"Developments in smoking cessation interventions for patients with chronic obstructive pulmonary disease in the past 5 years: A scoping review","volume":"16","author":"Feng","year":"2022","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104362","DOI":"10.1016\/j.ijnurstu.2022.104362","article-title":"Effects of different interventions on smoking cessation in chronic obstructive pulmonary disease patients: A systematic review and network meta-analysis","volume":"136","author":"Wei","year":"2022","journal-title":"Int. J. Nurs. Stud."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Priego-Jim\u00e9nez, S., Torres-Costoso, A., Guzm\u00e1n-Pav\u00f3n, M.J., Lorenzo-Garc\u00eda, P., Lucer\u00f3n-Lucas-Torres, M.I., and \u00c1lvarez-Bueno, C. (2022). Efficacy of Different Types of Physical Activity Interventions on Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Network Meta-Analysis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph192114539"},{"key":"ref_12","first-page":"CD001744","article-title":"Domiciliary oxygen for chronic obstructive pulmonary disease","volume":"2005","author":"Cranston","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1164\/rccm.202005-1854OC","article-title":"Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review","volume":"203","author":"Celli","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000355835","article-title":"The non-neuronal cholinergic system in health and disease","volume":"92","author":"Beckmann","year":"2013","journal-title":"Pharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-642-23274-9_14","article-title":"Muscarinic receptor antagonists: Effects on pulmonary function","volume":"208","author":"Buels","year":"2012","journal-title":"Handb Exp. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00418-008-0455-2","article-title":"The epithelial cholinergic system of the airways","volume":"130","author":"Kummer","year":"2008","journal-title":"Histochem. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Diabasana, Z., Perotin, J.M., Belgacemi, R., Ancel, J., Mulette, P., Delepine, G., Gosset, P., Maskos, U., Polette, M., and Desl\u00e9e, G. (2020). Nicotinic Receptor Subunits Atlas in the Adult Human Lung. Int. J. Mol. Sci., 21.","DOI":"10.1101\/2020.06.29.176750"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hollenhorst, M.I., and Krasteva-Christ, G. (2021). Nicotinic Acetylcholine Receptors in the Respiratory Tract. Molecules, 26.","DOI":"10.3390\/molecules26206097"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0034-5687(00)00207-3","article-title":"Transmission in autonomic ganglia","volume":"125","author":"Myers","year":"2001","journal-title":"Respir. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/09031936.00015108","article-title":"Muscarinic receptor subtypes in cilia-driven transport and airway epithelial development","volume":"33","author":"Klein","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_21","first-page":"L418","article-title":"Transient cholinergic glycoconjugate secretion from swine tracheal submucosal gland cells","volume":"262","author":"Dwyer","year":"1992","journal-title":"Am. J. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"681258","DOI":"10.1155\/2012\/681258","article-title":"Cholinergic regulation of airway inflammation and remodelling","volume":"2012","author":"Kolahian","year":"2012","journal-title":"J. Allergy"},{"key":"ref_23","first-page":"L970","article-title":"Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity","volume":"274","author":"Sato","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"L757","DOI":"10.1152\/ajplung.00409.2005","article-title":"Dimethyphenylpiperazinium, a nicotinic receptor agonist, downregulates inflammation in monocytes\/macrophages through PI3K and PLC chronic activation","volume":"291","author":"Blanchet","year":"2006","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1183\/13993003.00413-2015","article-title":"Anti-inflammatory effects of targeted lung denervation in patients with COPD","volume":"46","author":"Kistemaker","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1183\/09031936.00129307","article-title":"Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts","volume":"32","author":"Haag","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1165\/rcmb.2005-0343RC","article-title":"Muscarinic receptors mediate stimulation of human lung fibroblast proliferation","volume":"35","author":"Matthiesen","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.lfs.2007.02.034","article-title":"Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide","volume":"80","author":"Pieper","year":"2007","journal-title":"Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1165\/rcmb.2002-0128OC","article-title":"Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle","volume":"28","author":"Gosens","year":"2003","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1513\/AnnalsATS.201807-485AW","article-title":"Autopsy and Imaging Studies of Mucus in Asthma. Lessons Learned about Disease Mechanisms and the Role of Mucus in Airflow Obstruction","volume":"15","author":"Dunican","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4168\/aair.2022.14.2.196","article-title":"Mucus Plugs and Small Airway Dysfunction in Asthma, COPD, and Asthma-COPD Overlap","volume":"14","author":"Tamura","year":"2022","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_32","unstructured":"Brunton, L.L., Chabner, B.A., and Knollmann, B.C. (2015). Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, McGraw-Hill Education. [12th ed.]."},{"key":"ref_33","first-page":"CD006101","article-title":"Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease","volume":"2006","author":"Appleton","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_34","first-page":"CD009285","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","volume":"2014","author":"Karner","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","first-page":"CD009552","article-title":"Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease","volume":"2015","author":"Cheyne","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S48967","article-title":"Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: A systematic review and network meta-analysis","volume":"8","author":"Karabis","year":"2013","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00400","DOI":"10.1002\/prp2.400","article-title":"Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues","volume":"6","author":"Hegde","year":"2018","journal-title":"Pharmacol. Res. Perspect"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/ajhp\/zxab154","article-title":"Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease","volume":"78","author":"Hvisdas","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"667027","DOI":"10.3389\/fphar.2021.667027","article-title":"The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1164\/ajrccm.158.supplement_2.13tac110","article-title":"The beta-adrenoceptor","volume":"158","author":"Johnson","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000029295","article-title":"Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group","volume":"65","author":"Gross","year":"1998","journal-title":"Respiration"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1513\/AnnalsATS.201912-915OC","article-title":"Dual LABA\/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline","volume":"17","author":"Mammen","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s12325-020-01557-x","article-title":"Effects of Tiotropium\/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-\/Pooled Analyses","volume":"38","author":"Maltais","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/ph3030514","article-title":"Inhaled Corticosteroids","volume":"3","author":"Barnes","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_47","first-page":"CD002991","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","volume":"2012","author":"Yang","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_52","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease","volume":"2012","author":"Nannini","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/COPD.S130482","article-title":"LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: A systematic review and meta-analysis","volume":"12","author":"Rodrigo","year":"2017","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2015.11.004","article-title":"Interaction between corticosteroids and muscarinic antagonists in human airways","volume":"36","author":"Cazzola","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1517\/14656566.2014.899581","article-title":"Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease","volume":"15","author":"Matera","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced All-Cause Mortality in the ETHOS Trial of Budesonide\/Glycopyrrolate\/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1801230","DOI":"10.1183\/13993003.01230-2018","article-title":"Inhaled corticosteroid containing combinations and mortality in COPD","volume":"52","author":"Vestbo","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(21)00238-1","article-title":"Perplexing mortality data from triple therapy trials in COPD","volume":"9","author":"Suissa","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2174\/1381612823666170214105651","article-title":"Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences","volume":"23","author":"Contreras","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fphar.2020.00609","article-title":"Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors","volume":"11","author":"Joskova","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1073\/pnas.97.12.6751","article-title":"Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D","volume":"97","author":"Hansen","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-94-007-4549-0_8","article-title":"Effects of selective inhibition of PDE4 and PDE7 on airway reactivity and cough in healthy and ovalbumin-sensitized guinea pigs","volume":"756","author":"Mokry","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"L396","DOI":"10.1152\/ajplung.00125.2013","article-title":"Quercetin acutely relaxes airway smooth muscle and potentiates \u03b2-agonist-induced relaxation via dual phosphodiesterase inhibition of PLC\u03b2 and PDE4","volume":"305","author":"Townsend","year":"2013","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.21037\/jtd.2019.04.49","article-title":"Efficacy and safety profile of roflumilast in a real-world experience","volume":"11","author":"Cilli","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/thoraxjnl-2013-204155","article-title":"Benefits and harms of roflumilast in moderate to severe COPD","volume":"69","author":"Yu","year":"2014","journal-title":"Thorax"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0165-6147(02)02089-8","article-title":"4D or not 4D\u2014The emetogenic basis of PDE4 inhibitors uncovered?","volume":"23","author":"Giembycz","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"740803","DOI":"10.3389\/fphar.2021.740803","article-title":"Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease","volume":"12","author":"Facchinetti","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"838449","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/13543784.2019.1661990","article-title":"Ensifentrine (RPL554): An investigational PDE3\/4 inhibitor for the treatment of COPD","volume":"28","author":"Cazzola","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1801074","DOI":"10.1183\/13993003.01074-2018","article-title":"The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD","volume":"52","author":"Singh","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_76","unstructured":"Verona Pharma PLC (2023, January 04). Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD. Available online: https:\/\/www.veronapharma.com\/media\/verona-pharma-announces-ensifentrine-meets-primary-and-key."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.crphar.2022.100092","article-title":"The future of inhalation therapy in chronic obstructive pulmonary disease","volume":"3","author":"Cazzola","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Crim, C., Gotfried, M., Spangenthal, S., Watkins, M., Emmett, A., Crawford, C., Baidoo, C., and Castro-Santamaria, R. (2020). A randomized, controlled, repeat-dose study of batefenterol\/fluticasone furoate compared with placebo in the treatment of COPD. BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-1153-7"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2100972","DOI":"10.1183\/13993003.00972-2021","article-title":"The novel bronchodilator navafenterol: A phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD","volume":"59","author":"Singh","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/JEP.S259330","article-title":"Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease","volume":"12","author":"Ora","year":"2020","journal-title":"J. Exp. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Perikleous, E.P., Steiropoulos, P., Nena, E., and Paraskakis, E. (2022). Biologic Therapies in Pediatric Asthma. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060999"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s13346-021-00967-w","article-title":"Inhaled antibodies: Formulations require specific development to overcome instability due to nebulization","volume":"11","author":"Mayor","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"00576-2021","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_84","first-page":"363","article-title":"An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease","volume":"15","author":"Cazzola","year":"2021","journal-title":"Biologics"},{"key":"ref_85","first-page":"CD013432","article-title":"Anti-IL-5 therapies for chronic obstructive pulmonary disease","volume":"12","author":"Donovan","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaip.2019.01.036","article-title":"T2 Biologics for Chronic Obstructive Pulmonary Disease","volume":"7","author":"Yousuf","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S52387","article-title":"Dupilumab: A novel treatment for asthma","volume":"7","author":"Vatrella","year":"2014","journal-title":"J. Asthma Allergy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/B978-0-12-404717-4.00004-4","article-title":"The biology of thymic stromal lymphopoietin (TSLP)","volume":"66","author":"Ziegler","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.200501-147OC","article-title":"First study of infliximab treatment in patients with chronic obstructive pulmonary disease","volume":"172","author":"Postma","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/thoraxjnl-2012-202432","article-title":"TNF\u03b1 antagonists for acute exacerbations of COPD: A randomised double-blind controlled trial","volume":"68","author":"Aaron","year":"2013","journal-title":"Thorax"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2015.01.005","article-title":"Canakinumab for the treatment of chronic obstructive pulmonary disease","volume":"31","author":"Rogliani","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12931-017-0633-7","article-title":"A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease","volume":"18","author":"Calverley","year":"2017","journal-title":"Respir. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1378\/chest.126.3.926","article-title":"Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: A pilot study","volume":"126","author":"Mahler","year":"2004","journal-title":"Chest"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"151729","DOI":"10.1016\/j.aanat.2021.151729","article-title":"Preclinical studies and the function of IL-17 cytokines in COPD","volume":"237","author":"Ritzmann","year":"2021","journal-title":"Ann. Anat."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/3\/476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:15Z","timestamp":1760122095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/3\/476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":98,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["biom13030476"],"URL":"https:\/\/doi.org\/10.3390\/biom13030476","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]}}}